I. MODIFIED AGREEMENTS | |||
Biotech Co.* |
Pharma Co. (Country) | Change from original agreement | Terms/Details (Date) |
Cepheid Inc. |
Applera Corp. |
They amended patent license agreement relating to real-time thermal cycler instruments |
Cepheid's license now includes diagnosis and monitoring of HIV and hepatitis C infections; terms were not disclosed (6/29) |
CuraGen |
Bayer Pharmaceuticals Corp. |
Bayer announced its intention to license BAY 76-7171 (formerly CT052), a diabetes drug candidate |
CuraGen previously opted to receive a tiered royalty structure for the drug and no longer is contributing to development (7/19) |
Gen-Probe |
Bayer Healthcare LLC (Germany) |
The companies agreed to end a series of disputes involving patent litigations and contract arbitrations |
As part of the deal, Bayer will pay Gen- Probe certain lump sum royalties over 18 months; dispute areas included nucleic acid diagnostics and viral products (6/22) |
SkyePharma |
Mundipharma International Holdings Ltd. (UK) |
SkyePharma reacquired rights to DepoBupivacaine in Europe and other markets excluding the U.S., Canada and Japan |
SkyePharma is paying $5M for the rights; it intends to divest its injectables unit, of which the product is a part (6/30) |
I. TERMINATED AGREEMENTS | |||
Antisoma plc |
F. Hoffmann- La Roche Ltd. (Switzerland) |
Antisoma regained all rights to the investigational cancer drug AS1404 from Roche |
Antisoma plans to move the agent into Phase III trials in lung cancer; Roche also declined to exercise its option on another compound, R1550 (now AS1402) (6/4) |
EPIX |
Schering AG (Germany) |
Schering will not exercise its option for EPIX's fibrin-binding imaging agent EP-2104R |
EPIX has full rights to the product and intends to find a new partner (7/13) |
Neurocrine |
Pfizer Inc. |
They terminated December 2002 deal to develop and co-promote the insomnia drug candidate indiplon |
The move followed word from the FDA that additional testing likely would be needed to gain approval; Neurocrine regained all rights, and intends to continue development (6/22) |
NexMed Inc. |
Schering AG (Germany) |
Schering terminated a deal from July 2004 that gave it rights to Alprox-TD outside the U.S. and east Asia |
Alprox-TD is a topical treatment in development for erectile dysfunction; NexMed gets a $0.5M termination fee (6/26) |
SuperGen |
Wyeth |
They terminated deal under which Wyeth distributed the hairy cell leukemia product Nipent |
SuperGen paid Wyeth a $2.1M early termination fee, and has taken over distribution (6/6) |
Notes: | |||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
LSE = London Stock Exchange. |